Table 1 Baseline characteristics of patients (TCGA-PAAD).

From: Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma

Characteristics

Levels

Low-risk group

High-risk group

p value*

N = 89

N = 89

T stage, n (%)

T1

6 (6.9%)

1 (1.1%)

0.037

T2

16 (18.4%)

8 (9%)

 

T3

64 (73.6%)

78 (87.6%)

 

T4

1 (1.1%)

2 (2.2%)

 

N stage, n (%)

N0

27 (31.8%)

23 (26.1%)

0.517

N1

58 (68.2%)

65 (73.9%)

 

M stage, n (%)

M0

37 (97.4%)

42 (91.3%)

0.372

M1

1 (2.6%)

4 (8.7%)

 

Pathologic stage, n (%)

Stage I

16 (18.4%)

5 (5.7%)

0.022

Stage II

69 (79.3%)

77 (87.5%)

 

Stage III

1 (1.1%)

2 (2.3%)

 

Stage IV

1 (1.1%)

4 (4.5%)

 

Radiation therapy, n (%)

No

53 (65.4%)

65 (79.3%)

0.072

Yes

28 (34.6%)

17 (20.7%)

 

Primary therapy outcome, n (%)

PD

19 (28.8%)

30 (41.1%)

0.386

SD

5 (7.6%)

4 (5.5%)

 

PR

4 (6.1%)

6 (8.2%)

 

CR

38 (57.6%)

33 (45.2%)

 

Gender, n (%)

Female

40 (44.9%)

40 (44.9%)

1.000

Male

49 (55.1%)

49 (55.1%)

 

Age, n (%)

 ≤ 65

49 (55.1%)

44 (49.4%)

0.548

 > 65

40 (44.9%)

45 (50.6%)

 

Residual tumor, n (%)

R0

59 (70.2%)

48 (60%)

0.201

R1

24 (28.6%)

28 (35%)

 

R2

1 (1.2%)

4 (5%)

 

Histologic grade, n (%)

G1

23 (26.4%)

8 (9%)

0.001

G2

46 (52.9%)

49 (55.1%)

 

G3

16 (18.4%)

32 (36%)

 

G4

2 (2.3%)

0 (0%)

 

Anatomic neoplasm subdivision, n (%)

Head of Pancreas

72 (80.9%)

66 (74.2%)

0.369

Other

17 (19.1%)

23 (25.8%)

 

Smoker, n (%)

No

30 (44.1%)

35 (46.1%)

0.948

Yes

38 (55.9%)

41 (53.9%)

 

Alcohol history, n (%)

No

36 (43.9%)

29 (34.5%)

0.281

Yes

46 (56.1%)

55 (65.5%)

 

History of diabetes, n (%)

No

48 (69.6%)

60 (77.9%)

0.337

Yes

21 (30.4%)

17 (22.1%)

 

History of chronic pancreatitis, n (%)

No

61 (92.4%)

67 (89.3%)

0.733

Yes

5 (7.6%)

8 (10.7%)

 

Family history of cancer, n (%)

No

21 (39.6%)

26 (45.6%)

0.659

Yes

32 (60.4%)

31 (54.4%)

 
  1. Data are presented as n (%).
  2. PAAD pancreatic adenocarcinoma.
  3. *Compared with each group (Fisher exact test, or Pearson’s chi-square test). p value < 0.05 was considered statistically significant (highlighted in bold).
Back to article page